Draft:Astrego Diagnostics
Submission declined on 27 March 2024 by MicrobiologyMarcus (talk). This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|
Astrego Diagnostics AB
[edit]Astrego Diagnostics AB was a diagnostics company in Uppsala, Sweden. It is now a part of Sysmex Corporation under the namn Sysmex Astrego AB
The company developed products for Antibiotic Susceptibility Testing (AST).
Principle of detection
[edit]Bacterial cells are trapped in a microfluidic device that allows monitoring of growth of individual cells with phase contrast microscopy. The device have different sets of cell trapping channels that can be exposed to different antibiotics or different concentrations of antibiotic. If the bacteria are susceptible or not is determined by the growth rate response of the bacteria in one a set of cell channels, that are exposed to an antibiotic, as compared to the response in a set cell channels, that are not exposed to the antibiotic. The speed of the assay comes from measuring the length extension of individual bacteria and averaging over a few hundred bacteria to minimize the measurement error. These principles are described in the patent[1] by Elf, Baltekin and Andersson from 2015 and the corresponding publication. In contrast, traditional AST methods typically depend on cells to divide and multiply which takes longer time.
History
[edit]The company was founded in 2017 as a spinout from Uppsala University. The company’s first product was rapid test for Antibiotic Susceptibility for Uninary Tract Infection (UTI). The early development is described in a book by AMR declaration trust
In May 2022, Sysmex acquired Astrego to strengthen synergies between the companies and accelerate clinical application of the rapid antimicrobial susceptibility test. With the acquisition, Astrego became a wholly-owned subsidiary of Sysmex, and the company name changed to Sysmex Astrego AB[2].
- ^ PCT/SE2015/050685
- ^ "News details".
- in-depth (not just brief mentions about the subject or routine announcements)
- reliable
- secondary
- strictly independent of the subject
Make sure you add references that meet all four of these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.